---
layout: post
title: "Determination That BORTEZOMIB (Bortezomib) Solution, 2.5 Milligrams/Milliliter and 3.5 Milligrams/1.4 Milliliter (2.5 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 18:56:31 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-17746
original_published: 2023-08-18 00:00:00 +0000
significance: 8.00
---

# Determination That BORTEZOMIB (Bortezomib) Solution, 2.5 Milligrams/Milliliter and 3.5 Milligrams/1.4 Milliliter (2.5 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 18, 2023 00:00 UTC
**Document Number:** 2023-17746

## Summary

The Food and Drug Administration (FDA, Agency, or we) has determined that BORTEZOMIB (bortezomib) solution, 2.5 milligrams (mg)/ milliliter (mL) and 3.5 mg/1.4 mL (2.5 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for BORTEZOMIB (bortezomib) solution, 2.5 mg/mL and 3.5 mg/1.4 mL (2.5 mg/ mL), if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/18/2023-17746/determination-that-bortezomib-bortezomib-solution-25-milligramsmilliliter-and-35-milligrams14)
- API: https://www.federalregister.gov/api/v1/documents/2023-17746

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
